Gastroenterology 129 , 591608 (2005)
The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024
Supports Skin Health & Beauty from Within: Helps maintain healthy-looking skin by supporting normal skin function, elasticity, and moisture balance for a radiant appearance
Lawful compounding by 503A pharmacies becomes possible nationwide, subject to USP sterile-prep standards, beyond-use dating, and state requirements
Sed faucibus Sed faucibus ullamcorper mattis
Quality Control for Research Peptides Research peptides face unique quality control challenges due to their lack of standardized manufacturing requirements